CN104225033B - A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug - Google Patents
A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug Download PDFInfo
- Publication number
- CN104225033B CN104225033B CN201310235655.2A CN201310235655A CN104225033B CN 104225033 B CN104225033 B CN 104225033B CN 201310235655 A CN201310235655 A CN 201310235655A CN 104225033 B CN104225033 B CN 104225033B
- Authority
- CN
- China
- Prior art keywords
- portions
- chinese medicine
- hours
- spare
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of application of Chinese medicine composition in preparation treatment prostate cancer drug, which is made of the 8 taste Chinese medicine such as Radix Astragali, talcum, Prunella vulgaris, changes gas Li Shui, resolving hard lump.Studies have shown that Chinese medicine composition of the present invention can effectively treat prostate cancer.
Description
Technical field
The present invention relates to a kind of new application of Chinese medicine composition, for specific, it be related to a kind of Chinese medicine composition and preparing
Treat the application in prostate cancer drug.
Background technique
Prostate cancer is exactly the malignant tumour betided in human male prostate tissue, is that prostatic acini cell is extremely unordered
The result of growth.The disease incidence of prostate cancer has apparent geographical and racial difference.In developed countries and regions such as America and Europes, it
It is the most common malignant tumour of male, the death rate occupies the second of various cancers；In Asia, disease incidence is lower than west state
Family, but be in recent years in rise rapidly trend.
95% or more prostate cancer is to betide the gland cancer of prostate gland tissue, and development usually follows certain suitable
Sequence: it is confined in prostate-invades capsula prostatica-breakthrough capsula prostatica-infringement seminal vesicle-and be transferred to adjacent domain
Lymph node-is transferred to bone and other organs.Another important prostate cancer type is neuroendocrine carcinoma or is small thin
Born of the same parents' undifferentiated carcinoma, may be originating from neuroendocrine cell rather than prostate gland, this seed type prostate cancer generally relatively early go out
It now shifts and sends out, but do not secrete prostate specific antigen (PSA), and conventional prostate cancer therapy method acts on not it
Obviously, more sensitive to chemotherapy instead.
There are many treatment method, every kind for the treatment of methods its pros and cons for prostate cancer.According to the purpose for the treatment of, prostate cancer
Treatment method is divided into curative therapy and palliative therapy.
Surgical operation is most common curative therapy method, but doctor needs the figure and disease according to patient
Feature and the technology speciality of doctor select corresponding modus operandi, and not all patient is suitable for operative treatment.
Chemotherapeutics is frequently utilized for treating the patient for the metastatic prostate cancer that those resist endocrine therapy, to prolong
Slow tumour growth, extends the life of patient.Research has confirmed that docetaxel can effectively extend endocrine therapy repellence forefront
The life span of adenocarcinoma patients；And when the existence for the patient that Cabazitaxel can further extend those docetaxel treatment failures
Between, it is well known that the more serious adverse reaction of chemotherapeutics and expensive price are an important factor for restricting its application.
Traditional Chinese medicine thinks the generation of prostate cancer, related with the dirty acupoint functional disturbance such as kidney,spleen,liver, bladder.Comprehensive each doctor
Discussion, induce prostate cancer factor: first, be advanced in age and poor in health or excess of sexual intercourse,indulgence in sexual activities, nephrons virtual loss, disturbance in functioning of QI, it is entire unfavorable to open；The
Two, it is overworked, eating and drinking without temperance thus spleen deficiency and clean air does not rise, turbid yin difficulty drop；Third, inernal injuries caused by seven emotions, stagnation of QI due to depression of the liver, catharsis is not
And so that three burnt aqueous dysfunction of the spleen in transportation and transformation；4th, it is addicted to drink pungent, damp and hot to accumulate product, bladder of betting causes disturbance in qi transformation；5th, it loses
Essence is stopped and is not gone, and hemostasis blocks water channel, and with the passing of time damp heat and hemostasis, which are handed over, hinders, and stagnates into block, urethra and urinate
The disease of the retention of urines such as difficulty.
The present invention is the improvement invention carried out on the basis of Chinese patent ZL 200410091455.5, is drawn in full herein
The content recorded with the patent document.Chinese patent ZL 200410091455.5 does not record the Chinese medicine composition and treats in preparation
Application in prostate cancer drug.
Summary of the invention
It is an object of that present invention to provide a kind of application of Chinese medicine composition in preparation treatment prostate cancer drug.
Chinese medicine composition of the present invention is made of the bulk pharmaceutical chemicals of following weight ratio:
30-150 portions of Radix Astragali 7-28 portions of talcum 7-28 parts of the fruit of glossy privet of 10-40 portions of Prunella vulgaris
10-40 portions of semen litchi 1-4 portions of amber 3-15 parts of Cortex Phellodendri of 1.5-6 portions of cortex cinnamomi.
Preferably, the Chinese medicine composition is made of the bulk pharmaceutical chemicals of following weight ratio:
70 portions of Radix Astragali, 14 portions of talcum, 21 portions of Prunella vulgaris, 14 parts of the fruit of glossy privet
21 portions of semen litchi, 2.1 portions of amber, 2.8 portions of cortex cinnamomi, 7 parts of Cortex Phellodendri.
Or:
30 portions of Radix Astragali, 7 portions of talcum, 10 portions of Prunella vulgaris, 7 parts of the fruit of glossy privet
10 portions of semen litchi, 1 portion of amber, 1.5 portions of cortex cinnamomi, 3 parts of Cortex Phellodendri.
Or:
34 portions of Radix Astragali, 12 portions of talcum, 19 portions of Prunella vulgaris, 18 parts of the fruit of glossy privet
25 portions of semen litchi, 2.5 portions of amber, 4.5 portions of cortex cinnamomi, 13 parts of Cortex Phellodendri.
Or:
30 portions of Radix Astragali, 28 portions of talcum, 10 portions of Prunella vulgaris, 28 parts of the fruit of glossy privet
10 portions of semen litchi, 4 portions of amber, 1.5 portions of cortex cinnamomi, 15 parts of Cortex Phellodendri.
Chinese medicine that Chinese medicine of the present invention can be had same or similar effect replaces, and these medicinal materials can be according to
" national Chinese medicine preparation specification " or " dictionary of medicinal plant " processes.
The active constituent of Chinese medicine composition of the present invention can be by conventional extraction process [such as model Bi Ting " Chinese drugs agentia
Learn " (Shanghai Science Press December the 1st edition in 1997)] be made, it is highly preferred that the active constituent of the Chinese medicine composition is under
Column step is made:
(1), Chinese medicine is weighed in raw material medicines in portions by weight ratio, cleaned respectively, crushed；
(2), Radix Astragali, Cortex Phellodendri are taken, adds 50-70% ethyl alcohol, heating and refluxing extraction 1-3 times is 0.5-3 hours each, extracting solution mistake
Filter merges, and after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, spare；
(3), the fruit of glossy privet is taken, adds 6-10 times to measure 70-90% ethyl alcohol, heating and refluxing extraction 1-3 times, the time is that each 1-3 is small
When, extracting solution filtration merges, and after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, spare；
(4), cortex cinnamomi is taken, after adding 4-8 times to measure water immersion 1-2 hours, is extracted volatile oil 2-6 hours, the another device of volatile oil is collected,
Aqueous extract is collected by filtration, and residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 8-10 times to measure water, decoct twice, first time 1-3
Hour, second 1-2 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, being condensed into relative density is
1.20-1.25 clear cream, it is spare；
(6), talcum, amber are taken, 100 mesh fine powders are ground into, it is spare；
Clear cream obtained by step (2), clear cream and step obtained by volatile oil, step (5) obtained by clear cream, step (4) obtained by step (3)
Suddenly fine powder obtained by (6) collectively forms the active constituent of Chinese medicine composition of the present invention.
The preparation formulation of Chinese medicine composition of the present invention is capsule, tablet, oral solution or pill.
The present invention also provides the preparation methods of the Chinese medicinal composition capsules agent:
(1), the Chinese medicine is taken, is cleaned respectively, is crushed, amount weighs in proportion；
(2), Radix Astragali, Cortex Phellodendri are taken, 50-70% ethyl alcohol is added, heating and refluxing extraction 1-3 times is 0.5-3 hours each, it is preferable that
Heating and refluxing extraction 1-2 times, for the first time plus 8-12 times is measured, and is extracted 1-3 hours, and for the second time plus 6-9 times is measured, and is extracted 0.5-2 hours,
Extracting solution filtering, merges, and after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, is dried in vacuo, preferably
Ground is put into vacuum oven, is dried under reduced pressure under the conditions of 60-70 DEG C of temperature, vacuum degree 0.04-0.06Mpa, dry cream is spare；
(3), the fruit of glossy privet is taken, adds 6-10 times to measure 70-90% ethyl alcohol, heating and refluxing extraction 1-3 times, the time is that each 1-3 is small
When, extracting solution filtration merges, and after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, vacuum drying is excellent
Selection of land is put into vacuum oven, is dried under reduced pressure under the conditions of 60-70 DEG C of temperature, vacuum degree 0.04-0.06Mpa, dry cream is spare；
(4), cortex cinnamomi is taken, after adding 4-8 times to measure water immersion 1-2 hours, is extracted volatile oil 2-6 hours, the another device of volatile oil is collected,
Oil yield must not be less than l.0%, and aqueous extract is collected by filtration, and residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 8-10 times to measure water, decoct twice, first time 1-3
Hour, second 1-2 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, being condensed into relative density is
The clear cream of 1.20-1.25, vacuum drying, it is preferable that it is put into vacuum oven, at 60-70 DEG C of temperature, vacuum degree 0.04-
It is dried under reduced pressure under the conditions of 0.06Mpa, gets dry extract and step (2) get dry extract, step (3) got dry extract co-grinding is at 100
Mesh powder is spare；
(6), talcum, amber are taken, 100 mesh powder are ground into, it is spare；
(7), fine powder obtained by dried cream powder obtained by step (5), step (6) and appropriate amount of auxiliary materials are uniformly mixed, are made with 80% ethyl alcohol
Adhesive, High Shear Mixer Granulator, 60-70 DEG C of drying, whole grain；
(8), sift out fine powder, spray into volatile oil obtained by step (4), be uniformly mixed with particle, it is closed, it is encapsulated to get.
Chinese medicine composition of the present invention, the latin name and its processing method of the bulk pharmaceutical chemicals as active component from " in
Medicine voluminous dictionary " (in July, 1977, the first edition, Shanghai science tech publishing house) and " Chinese Pharmacopoeia " (version in 2005, chemical industry
Publishing house).
Chinese medicine composition of the present invention can also preparation process routinely, for example, Fan Biting " pharmacy of Chinese materia medica " (on
Extra large Science Press December the 1st edition in 1997) preparation process that records, pharmaceutically acceptable any conventional formulation, example is made
Such as capsule, tablet, granule, powder, oral solution or pill.
In application of the invention, the preparation formulation of the Chinese medicine composition is capsule, tablet, granule, powder, takes orally
Pharmaceutically acceptable auxiliary material need to be added to can be realized above-mentioned dosage form in liquid or pill when preparing these dosage forms, such as: it fills out
Fill agent, disintegrating agent, lubricant, suspending agent, adhesive, sweetener, corrigent, preservative, matrix etc..Filler include: starch,
Pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；Disintegrating agent includes: starch, pregelatinized starch, micro-
Crystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium
Deng；Lubricant includes: magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc.；Suspending agent includes: polyvinyl pyrrole
Alkanone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Adhesive includes starch slurry, polyvinylpyrrolidine
Ketone, hydroxypropyl methyl cellulose etc.；Sweetener includes: saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.；Flavoring
Agent includes: sweetener and various essence；Preservative includes: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzene
Prick fixed, eucalyptus oil of bromine ammonium, acetic acid chloroethene etc.；Matrix includes: PEG6000, PEG4000, insect wax etc..For the Chinese medicine for making above-mentioned dosage form
Preparation can be realized, need to be added when preparing these dosage forms pharmaceutically acceptable other auxiliary materials (Fan Biting " pharmacy of Chinese materia medica ", on
The auxiliary material that each dosage form is recorded in extra large Science Press December the 1st edition in 1997).
For the activity for illustrating traditional Chinese medicine composition for treating prostate cancer of the present invention, with by medicine obtained by embodiment method
Object (drug hereinafter referred to as of the present invention) has carried out following test.
One, clinical test 1
1, clinical data
1.1 general information: 84 patients are the patients with prostate cancer that Hebei Yi Ling hospital accepts for medical treatment in 2006-2010,
Age 45-70 years old, average out to (58.63 ± 5.23) year, cut off through aspiration biopsy of prostatic gland and per urethra prostatic secretions
Histopathology is made a definite diagnosis.
2 treatment methods
Oral drug of the present invention (being prepared according to the prescription and method of embodiment 1), it is 2-4 each, 3 times a day, two months
It is as a treatment course, curative effect is counted after one course for the treatment of of overview.
3 observation of curative effect
3.1 observation index
3.1.1 serum PSA (PSA): every patient treats forward and backward early morning and extracts ulnar vein blood on an empty stomach
2 mL, inspection.
3.1.2 digital rectal examination: every patient treats forward and backward row digital rectal examination, understands prostate lump situation and simultaneously records.
3.1.3 prostate B ultrasound: it is super that every patient treats forward and backward row prostate B, understands prostate lump situation simultaneously
Record.
All data of 3.2 statistical methods handle data using statistic software SPSS 11.5；Measurement data is examined using t
It tests；Technical data uses x2It examines；Parameter is usedIt indicates.
4, result
The 4.1 forward and backward blood-serum P SA for the treatment of have significant meaning (P < 0.05) compared to difference, the results are shown in Table 1.
Table 1: pretherapy and post-treatment blood and urine biochemical indexes variation is compared
| Testing index | Number of cases | Before treatment (ng/ml) | After treatment (ng/ml) |
| Blood-serum P SA | 84 | 30.15±11.87 | 10.90±5.36 |
The 4.2 forward and backward prostate Tumor sizes for the treatment of are compared, and are had significant difference (P < 0.05), be the results are shown in Table 2.
Table 2: the size for treating forward and backward prostate lump compares
| Testing index | Number of cases | Before treatment (cm) | After treatment (cm) |
| Digital rectal examination | 84 | 1.21±0.35 | 0.61±0.05 |
| Prostate B ultrasound | 84 | 1.11±0.57 | 0.52±0.02 |
Serum PSA (PSA), prostate Tumor size after preceding and treatment it can be concluded that, are treated by upper table
It compares, there is significant difference P < 0.05, show that drug of the present invention can effectively treat prostate cancer.
Two, clinical test 2
1, clinical data
1.1 general information: collecting 96 patients is the prostate cancer that Hebei Yi Ling hospital accepts for medical treatment in 2008-2012
Patient, the age 55-75 years old, average out to (65.29 ± 6.43) year, all patients through the iconographies such as CT, color ultrasound and clinical examination,
Body, bone scanning put and exempt from PSA inspection, wear pathology through prostate needle and make a definite diagnosis.It is just to control patient, clinical symptoms are tired to urinate
Based on the irritations sign of bladder such as difficult and frequent micturition, urgent urination, it is seen that gross hematuria and merging ostalgia person.Patient is randomly divided into 4 groups, every group
24.
2 treatment methods
Positive drug group: oral Flutamide, each 250mg, 3 times a day；
Test group 1: oral drug (being prepared according to the prescription and method of embodiment 1) of the present invention, it is 2-4 each, daily 3
Secondary, two months as a treatment course, counts curative effect after one course for the treatment of of overview.
Test group 2: oral drug (being prepared according to the prescription and method of embodiment 2) of the present invention, each 2-4 piece, daily 3
Secondary, two months as a treatment course, counts curative effect after one course for the treatment of of overview.
Test group 3: oral drug (being prepared according to the prescription and method of embodiment 3) of the present invention, each 10-15ml, daily 3
Secondary, two months as a treatment course, counts curative effect after one course for the treatment of of overview.
3 observation of curative effect
3.1 observation index: observation controlled micturition is difficult, and (frequent micturition, enuresis nocturna increase, splitting of urinary stream, and urine end is dripping not to the utmost
Deng)；The variation of Bone tumour stove pain；It takes medicine after 30d and 60d, PSA (BAYER) kit measures blood-serum P SA respectively；Anus examines understanding
Prostate size, quality.Check blood routine, liver function, renal function；X-ray judges the variation of prostate cancer with osseous metastasis lesion.Acquisition
Anus is avoided to examine inspection, plug in catheter and prostate biopsy etc. before blood specimen.
3.2 criterions of therapeutical effect: the one for having following change is effective: 1. anus digital examination and B ultrasound confirm prostate volume reduce >
50% or lesion tubercle disappearance person；2. the dysuria symptom person of being obviously improved；3. Bone tumour stove pain alleviation 2 months or more persons；④
Blood PSA declines 50% or more person；5. X-ray film Bone tumour lesion area reduces > 50%；6. the systemic conditions person of being obviously improved.It is aobvious
Effect is 2 above improvement persons of index.
All data of 3.3 statistical methods handle data using statistic software SPSS 11.5；Measurement data is examined using t
It tests；Technical data uses x2It examines；Parameter is usedIt indicates.
4, result
The variation of 4.1 pretherapy and post-treatment prostate volumes: the prostate volume of positive drug group and each test group is equal after the treatment
Be obviously reduced, respectively reduce 52.8% and 66.5%, 64.7%, 68.3%, with treatment before compared with have significant difference (P <
0.05), each test group with positive drug group before decreasing column body of gland product compared on also have significant difference (P < 0.05), as a result see
Table 3.
Table 3: pretherapy and post-treatment prostate volume compare (, n=24)
| Grouping | Number of cases | Prostate volume/ml before treating | Prostate volume/ml after treatment | Minification/% |
| Positive drug group | 24 | 86.7±5.2 | 40.72±3.7* | 52.8 |
| Test group 1 | 24 | 87.3±4.8 | 29.25±3.4*# | 66.5# |
| Test group 2 | 24 | 85.1±5.1 | 30.59±4.2*# | 64.7# |
| Test group 3 | 24 | 86.2±5.3 | 31.34±4.1*# | 68.3# |
Note: P < 0.05 * compared with before treatment, compared with positive drug group# P<0.05。
4.2 pretherapy and post-treatment dysuric variations: it is 18 patients that every group is dysuric before treatment, after treatment, sun
Property medicine group and the dysuria number of each test group drop to 2 and 1,1,1, have significant difference compared with before treatment
(P < 0.01), there was no significant difference with positive drug group for each test group on reducing dysuria number, the results are shown in Table 4.
Table 4: pretherapy and post-treatment dysuric comparison (n=24)
| Grouping | Number of cases | Before treatment | After treatment |
| Positive drug group | 24 | 18(75%) | 2*(8.3%) |
| Test group 1 | 24 | 18(75%) | 1*(4.2%) |
| Test group 2 | 24 | 18(75%) | 1*(4.2%) |
| Test group 3 | 24 | 18(75%) | 1*(4.2%) |
Note: P < 0.01 * compared with before treatment, compared with positive drug group# P<0.05。
4.3 pretherapy and post-treatment Bone tumour stove pain relieving times: after positive drug group and the treatment of each test group, Bone tumour stove pain
Alleviate number of days and respectively reached 251d and 328d, 339d, 345d, each test group have compared with positive drug group statistical difference P <
0.05, it the results are shown in Table 5.
Table 5: after treatment Bone tumour stove pain relieving time comparison (, n=24)
| Grouping | Number of cases | Remission time (d) |
| Positive drug group | 24 | 251±12 |
| Test group 1 | 24 | 328±18# |
| Test group 2 | 24 | 339±21# |
| Test group 3 | 24 | 345±20# |
Note: compared with positive drug group# P<0.05。
4.4 pretherapy and post-treatment serum f/tPSA values compare: the f/tPSA value of positive drug group and each test group is compared with before treatment
Have significant difference (P < 0.05), each test group also have compared with the f/tPSA value of positive drug group significant difference (P <
0.05) 6, be the results are shown in Table.
Table 6: pretherapy and post-treatment serum f/tPSA value compare (, n=24)
| Grouping | Number of cases | Before treatment (ng/ml) | After treatment (ng/ml) |
| Positive drug group | 24 | 0.13±0.08 | 0.20±0.05* |
| Test group 1 | 24 | 0.12±0.02 | 0.28±0.04*# |
| Test group 2 | 24 | 0.12±0.05 | 0.31±0.05*# |
| Test group 3 | 24 | 0.13±0.04 | 0.27±0.06*# |
Note: P < 0.05 * compared with before treatment, compared with positive drug group# P<0.05。
4.5 total effects compare: the total effective rate of positive drug is 66.6%, and the effective percentage of each test group respectively reaches
91.7%, 95.8%, 91.7%, with significant difference P < 0.05 compared with positive drug group, it the results are shown in Table 7.
Table 7: treatment total effects compare (n=24)
| Grouping | Number of cases | Effective number of cases | Effective number of cases | Total effective number of cases |
| Positive drug group | 24 | 5(20.8%) | 11(45.8%) | 16(66.6%) |
| Test group 1 | 24 | 12(50.0%) | 10(41.7%) | 22(91.7%)# |
| Test group 2 | 24 | 13(54.2%) | 10(41.7%) | 23(95.8%)# |
| Test group 3 | 24 | 13(54.2%) | 9(37.5%) | 22(91.7%)# |
Note: compared with positive drug group# P<0.05。
5 summarize: by the above test result it is found that each test group is reducing prostate volume, alleviating Bone tumour stove pain
Significant difference P < 0.05, explanation are all had compared with positive drug group in terms of time, the content for improving serum f/tPSA, total effective rate
The effect of drug therapy prostate cancer of the present invention is better than conventional Western medicine.Drug therapy forefront of the present invention is confirmed by clinical test
Gland cancer tool has a better effect.
Specific embodiment
Embodiment 1: the preparation of medicine capsule of the present invention
Prescription:
70 grams of Radix Astragali, 14 grams of talcum, 21 grams of Prunella vulgaris, 14 grams of the fruit of glossy privet
21 grams of semen litchi, 2.1 grams of amber, 2.8 grams of cortex cinnamomi, 7 grams of Cortex Phellodendri
Preparation method:
(1), Chinese medicine is weighed by recipe quantity, cleaned respectively, crushed；
(2), Radix Astragali, Cortex Phellodendri are taken, 60% ethyl alcohol is added, heating and refluxing extraction 2 times, for the first time plus 10 times are measured, it extracts 2 hours, the
Secondary plus 8 times of amounts, are extracted 1 hour, and extracting solution filtering merges, and after ethyl alcohol is recovered under reduced pressure, being condensed into relative density is 1.20-
1.25 clear cream, is put into vacuum oven, is dried under reduced pressure under the conditions of 65 DEG C of temperature, vacuum degree 0.05Mpa, dry cream is spare；
(3), the fruit of glossy privet is taken, adds 8 times of 80% ethyl alcohol of amount, heating and refluxing extraction 2 times, the time is 2 hours every time, extracting solution filter
It crosses, merges, after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, vacuum oven is put into, in temperature
It 65 DEG C, is dried under reduced pressure under the conditions of vacuum degree 0.05Mpa, dry cream is spare；
(4), cortex cinnamomi is taken, after adding 6 times of amount water to impregnate 1 hour, is extracted volatile oil 4 hours, the another device of volatile oil is collected, oil yield
Must not be less than l.0%, aqueous extract is collected by filtration, and residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 9 times of amount water, decoct twice, 2 hours for the first time,
Second 1.5 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, and being condensed into relative density is 1.20-1.25
Clear cream, be put into vacuum oven, be dried under reduced pressure under the conditions of 65 DEG C of temperature, vacuum degree 0.05Mpa, got dry extract and step
(2) get dry extract, step (3) got dry extract co-grinding it is spare at 100 mesh powder；
(6), talcum, amber are taken, 100 mesh powder are ground into, it is spare；
(7), fine powder obtained by dried cream powder obtained by step (5), step (6) and appropriate amount of auxiliary materials are uniformly mixed, are made with 80% ethyl alcohol
Adhesive, High Shear Mixer Granulator, 60-70 DEG C of drying, whole grain；
(8), sift out fine powder, spray into volatile oil obtained by step (4), be uniformly mixed with particle, it is closed, it is encapsulated to get.
Embodiment 2: the preparation of medicinal tablet of the present invention
Prescription:
30 grams of Radix Astragali, 7 grams of talcum, 10 grams of Prunella vulgaris, 7 grams of the fruit of glossy privet
10 grams of semen litchi, 1 gram of amber, 1.5 grams of cortex cinnamomi, 3 grams of Cortex Phellodendri
Preparation method:
(1), Chinese medicine is weighed by recipe quantity, cleaned respectively, crushed；
(2), Radix Astragali, Cortex Phellodendri are taken, 60% ethyl alcohol is added, heating and refluxing extraction 2 times, for the first time plus 9 times are measured, it extracts 3 hours, the
Secondary plus 8 times of amounts, are extracted 1.5 hours, and extracting solution filtering merges, and after ethyl alcohol is recovered under reduced pressure, being condensed into relative density is 1.20-
1.25 clear cream, it is spare；
(3), the fruit of glossy privet is taken, adds 7 times of 80% ethyl alcohol of amount, heating and refluxing extraction 2 times, the time is 2 hours every time, extracting solution filter
It crosses, merges, after ethyl alcohol is recovered under reduced pressure, be condensed into the clear cream that relative density is 1.20-1.25, it is spare；
(4), cortex cinnamomi is taken, after adding 6 times of amount water to impregnate 1.5 hours, is extracted volatile oil 5 hours, the another device of volatile oil is collected, and water mentions
Liquid is taken to be collected by filtration, residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 9 times of amount water, decoct twice, 2 hours for the first time,
Second 1.5 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, and being condensed into relative density is 1.20-1.25
Clear cream, it is spare；
(6), talcum, amber are taken, 100 mesh fine powders are ground into, it is spare；
(7), routinely tablet is made in formulation method.
Embodiment 3: the preparation of medicine oral liquid of the present invention
Prescription:
34 grams of Radix Astragali, 12 grams of talcum, 19 grams of Prunella vulgaris, 18 grams of the fruit of glossy privet
25 grams of semen litchi, 2.5 grams of amber, 4.5 grams of cortex cinnamomi, 13 grams of Cortex Phellodendri
Preparation method: routinely oral solution is made in formulation method.
Embodiment 4: the preparation of bolus of drug of the present invention
Prescription:
30 grams of Radix Astragali, 28 grams of talcum, 10 grams of Prunella vulgaris, 28 grams of the fruit of glossy privet
10 grams of semen litchi, 4 grams of amber, 1.5 grams of cortex cinnamomi, 15 grams of Cortex Phellodendri
Preparation method: routinely pill is made in formulation method.
Embodiment 5: the preparation of bolus of drug of the present invention
Prescription:
150 grams of Radix Astragali, 28 grams of talcum, 40 grams of Prunella vulgaris, 7 grams of the fruit of glossy privet
40 grams of semen litchi, 1 gram of amber, 6 grams of cortex cinnamomi, 3 grams of Cortex Phellodendri
Preparation method: routinely pill is made in formulation method.
Claims (10)
1. a kind of application of Chinese medicine composition in preparation treatment prostate cancer drug, it is characterised in that the Chinese medicine composition is
Made of the bulk pharmaceutical chemicals of following weight ratio:
30-150 portions of Radix Astragali 7-28 portions of talcum 7-28 parts of the fruit of glossy privet of 10-40 portions of Prunella vulgaris
10-40 portions of semen litchi 1-4 portions of amber 3-15 parts of Cortex Phellodendri of 1.5-6 portions of cortex cinnamomi.
2. application as described in claim 1, it is characterised in that the Chinese medicine composition is by the raw material of following weight ratio
Medicine is made:
70 portions of Radix Astragali, 14 portions of talcum, 21 portions of Prunella vulgaris, 14 parts of the fruit of glossy privet
21 portions of semen litchi, 2.1 portions of amber, 2.8 portions of cortex cinnamomi, 7 parts of Cortex Phellodendri.
3. application as described in claim 1, it is characterised in that the Chinese medicine composition is by the raw material of following weight ratio
Medicine is made:
30 portions of Radix Astragali, 7 portions of talcum, 10 portions of Prunella vulgaris, 7 parts of the fruit of glossy privet
10 portions of semen litchi, 1 portion of amber, 1.5 portions of cortex cinnamomi, 3 parts of Cortex Phellodendri.
4. application as described in claim 1, it is characterised in that the Chinese medicine composition is by the raw material of following weight ratio
Medicine is made:
34 portions of Radix Astragali, 12 portions of talcum, 19 portions of Prunella vulgaris, 18 parts of the fruit of glossy privet
25 portions of semen litchi, 2.5 portions of amber, 4.5 portions of cortex cinnamomi, 13 parts of Cortex Phellodendri.
5. application as described in claim 1, it is characterised in that the Chinese medicine composition is by the raw material of following weight ratio
Medicine is made:
30 portions of Radix Astragali, 28 portions of talcum, 10 portions of Prunella vulgaris, 28 parts of the fruit of glossy privet
10 portions of semen litchi, 4 portions of amber, 1.5 portions of cortex cinnamomi, 15 parts of Cortex Phellodendri.
6. application according to any one of claims 1 to 5, it is characterised in that the active constituent of the Chinese medicine composition be by
Made of following steps:
(1), Chinese medicine is weighed in raw material medicines in portions by weight ratio, cleaned respectively, crushed；
(2), Radix Astragali, Cortex Phellodendri are taken, 50-70% ethyl alcohol is added, heating and refluxing extraction 1-3 times is 0.5-3 hours each, extracting solution filtering,
Merge, after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, it is spare；
(3), the fruit of glossy privet is taken, adds 6-10 times to measure 70-90% ethyl alcohol, heating and refluxing extraction 1-3 times, the time is each 1-3 hours, is mentioned
It takes liquid to filter, merges, after ethyl alcohol is recovered under reduced pressure, be condensed into the clear cream that relative density is 1.20-1.25, it is spare；
(4), cortex cinnamomi is taken, after adding 4-8 times to measure water immersion 1-2 hours, is extracted volatile oil 2-6 hours, the another device of volatile oil is collected, and water mentions
Liquid is taken to be collected by filtration, residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 8-10 times to measure water, decoct twice, first time 1-3 hour,
Second 1-2 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, and being condensed into relative density is 1.20-1.25
Clear cream, it is spare；
(6), talcum, amber are taken, 100 mesh fine powders are ground into, it is spare；
Clear cream obtained by step (2), clear cream and step obtained by volatile oil, step (5) obtained by clear cream, step (4) obtained by step (3)
(6) gained fine powder collectively forms the active constituent of the Chinese medicine composition.
7. application according to any one of claims 1 to 5, it is characterised in that the preparation formulation of the Chinese medicine composition is glue
Wafer, tablet, oral solution or pill.
8. the use as claimed in claim 7, it is characterised in that the capsule is made of following steps:
(1), the Chinese medicine is taken, is cleaned respectively, is crushed, amount weighs in proportion；
(2), Radix Astragali, Cortex Phellodendri are taken, 50-70% ethyl alcohol is added, heating and refluxing extraction 1-3 times is 0.5-3 hours each, extracting solution filtering,
Merge, after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, is dried in vacuo, dry cream is spare；
(3), the fruit of glossy privet is taken, adds 6-10 times to measure 70-90% ethyl alcohol, heating and refluxing extraction 1-3 times, the time is each 1-3 hours, is mentioned
It takes liquid to filter, merges, after ethyl alcohol is recovered under reduced pressure, is condensed into the clear cream that relative density is 1.20-1.25, is dried in vacuo, dry cream is standby
With；
(4), cortex cinnamomi is taken, after adding 4-8 times to measure water immersion 1-2 hours, is extracted volatile oil 2-6 hours, the another device of volatile oil is collected, fuel-displaced
Rate must not be less than l.0%, and aqueous extract is collected by filtration, and residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 8-10 times to measure water, decoct twice, first time 1-3 hour,
Second 1-2 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, and being condensed into relative density is 1.20-1.25
Clear cream, vacuum drying, get dry extract get dry extract with step (2), step (3) got dry extract co-grinding it is standby at 100 mesh powder
With；
(6), talcum, amber are taken, 100 mesh powder are ground into, it is spare；
(7), fine powder obtained by dried cream powder obtained by step (5), step (6) and appropriate amount of auxiliary materials are uniformly mixed, are bonded with 80% ethyl alcohol
Agent, High Shear Mixer Granulator, 60-70 DEG C of drying, whole grain；
(8), sift out fine powder, spray into volatile oil obtained by step (4), be uniformly mixed with particle, it is closed, it is encapsulated to get.
9. the use as claimed in claim 7, it is characterised in that the capsule is made of following steps:
(1), Chinese medicine is weighed by recipe quantity, cleaned respectively, crushed；
(2), Radix Astragali, Cortex Phellodendri are taken, 60% ethyl alcohol is added, heating and refluxing extraction 2 times, for the first time plus 10 times are measured, and are extracted 2 hours, second
Add 8 times of amounts, extract 1 hour, extracting solution filtering merges, and after ethyl alcohol is recovered under reduced pressure, being condensed into relative density is 1.20-1.25's
Clear cream is put into vacuum oven, is dried under reduced pressure under the conditions of 65 DEG C of temperature, vacuum degree 0.05Mpa, dry cream is spare；
(3), the fruit of glossy privet is taken, 8 times of 80% ethyl alcohol of amount are added, heating and refluxing extraction 2 times, the time is 2 hours every time, and extracting solution filtration is closed
And after ethyl alcohol is recovered under reduced pressure, it is condensed into the clear cream that relative density is 1.20-1.25, is put into vacuum oven, at 65 DEG C of temperature,
It is dried under reduced pressure under the conditions of vacuum degree 0.05Mpa, dry cream is spare；
(4), cortex cinnamomi is taken, after adding 6 times of amount water to impregnate 1 hour, is extracted volatile oil 4 hours, the another device of volatile oil is collected, and oil yield must not
Less than l.0%, aqueous extract is collected by filtration, and residue is spare；
(5), it takes Prunella vulgaris, semen litchi and step (4) residue obtained, adds 9 times of amount water, decoct twice, 2 hours for the first time, second
Secondary 1.5 hours, extracting solution filtering merged, step (4) obtained aqueous solution is added, and being condensed into relative density is the clear of 1.20-1.25
Cream is put into vacuum oven, is dried under reduced pressure under the conditions of 65 DEG C of temperature, vacuum degree 0.05Mpa, gets dry extract and step (2) institute
Get dry extract, step (3) got dry extract co-grinding it is spare at 100 mesh powder；
(6), talcum, amber are taken, 100 mesh powder are ground into, it is spare；
(7), fine powder obtained by dried cream powder obtained by step (5), step (6) and appropriate amount of auxiliary materials are uniformly mixed, are bonded with 80% ethyl alcohol
Agent, High Shear Mixer Granulator, 60-70 DEG C of drying, whole grain；
(8), sift out fine powder, spray into volatile oil obtained by step (4), be uniformly mixed with particle, it is closed, it is encapsulated to get.
10. application according to any one of claims 1 to 5, it is characterised in that the Chinese medicine composition alleviates forefront in preparation
Application in gland cancer Bone tumour stove pain medication.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310235655.2A CN104225033B (en) | 2013-06-15 | 2013-06-15 | A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310235655.2A CN104225033B (en) | 2013-06-15 | 2013-06-15 | A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104225033A CN104225033A (en) | 2014-12-24 |
| CN104225033B true CN104225033B (en) | 2019-02-01 |
Family
ID=52214509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310235655.2A Active CN104225033B (en) | 2013-06-15 | 2013-06-15 | A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104225033B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106290599B (en) * | 2015-06-12 | 2020-07-21 | 石家庄以岭药业股份有限公司 | Content determination method of traditional Chinese medicine composition |
| CN107802689A (en) * | 2016-09-05 | 2018-03-16 | 广州白云山中药业有限公司 | Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer |
| CN111840401B (en) * | 2019-04-22 | 2023-05-09 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating gastrointestinal hemorrhage |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN101618103A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050260285A1 (en) * | 2004-05-21 | 2005-11-24 | Dimateeo-Leggio Giovina | Healthy prostate formula |
-
2013
- 2013-06-15 CN CN201310235655.2A patent/CN104225033B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN101618103A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104225033A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112043804A (en) | Dampness-resolving toxin-vanquishing granules, preparation method thereof and antiviral drug | |
| CN101618110B (en) | Application of Chinese medicinal composition in preparing medicament for treating urinary calculi | |
| CN111729055A (en) | Preparation method and application of traditional Chinese medicine composition for eliminating dampness and removing toxicity | |
| CN104225033B (en) | A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug | |
| CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
| CN106038637A (en) | Pharmaceutical composition for treating breast cancer | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN102416045A (en) | Traditional Chinese medicine composition used for treating urinary system infection, and preparation method thereof | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN102274459B (en) | Chinese medicinal preparation for treating uterine fibroid and preparation method thereof | |
| CN101590173B (en) | Application of traditional Chinese medicine composition in preparing medicine for treating hypertensive intracerebral hemorrhage | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN116407595B (en) | Traditional Chinese medicine composition for treating triple negative breast cancer, traditional Chinese medicine preparation and application thereof | |
| CN117180379B (en) | Traditional Chinese medicine composition for treating qi deficiency and toxin stagnation type hashimoto thyroiditis and application thereof | |
| CN104225034B (en) | Application of composition in preparing medicine for treating non-infectious urethral syndrome | |
| CN105343194A (en) | Pharmaceutical composition for treating stomach cancer and preparation method thereof | |
| CN105497251A (en) | Medicine composition for treating functional dyspepsia | |
| CN105168397A (en) | Medicine composition for preventing and treating nephrosis | |
| CN103272167B (en) | Medicine for curing chronic diarrhea and preparation method thereof | |
| CN117379505A (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN104225035A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating male infertility | |
| CN102309683B (en) | Application of traditional Chinese medicinal composition in preparing medicines for treating hysteromyoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |